Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06076837 · ClinicalTrials.gov registry record · Phase 1

The Seven Trial: Exploiting the Unfolded Protein Response

A Phase 1 study of Pancreatic Cancer Metastatic and Pancreatic Adenocarcinoma Metastatic, sponsored by HonorHealth Research Institute.

Active
Registry status
Phase 1
Development phase
6
Enrollment target
1
Study location

NCT06076837 is a Phase 1 study of Pancreatic Cancer Metastatic and Pancreatic Adenocarcinoma Metastatic that is active but no longer recruiting, run by HonorHealth Research Institute. The registered enrollment target is 6 participants, below the 131-participant average among 9 other Pancreatic Cancer Metastatic trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06076837, a Phase 1 study of Pancreatic Cancer Metastatic and Pancreatic Adenocarcinoma Metastatic, is active but no longer recruiting, sponsored by HonorHealth Research Institute.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
6 participants
Enrollment target
1
Study location

Study Summary

The goal of this investigator initiated interventional study is to improve the response to the anticancer treatments (chemotherapy) in people who have previously untreated metastatic pancreas cancer. The main question it aims to answer is: • Do new types of immune-based therapies, called botensilimab, and balstilimab, when given in combination with chemotherapy consisting of nab-paclitaxel + gemcitabine + cisplatin, and oral medications of chloroquine and celecoxib help patients with previously untreated metastatic pancreatic cancer? Participants will be administered two immune-based therapies: * Botensilimab (also referred to as AGEN1811) * Balstilimab (also referred to as AGEN2034) Patients will be evaluated when given in combination with: * Triple chemotherapy (nab-paclitaxel + gemcitabine + cisplatin), plus two oral medications: * chloroquine * celecoxib

Conditions Studied

Pancreatic Cancer Metastatic Pancreatic Adenocarcinoma Metastatic

Interventions

  • DRUG Celecoxib
  • DRUG Balstilimab
  • DRUG Nab paclitaxel
  • DRUG Botensilimab
  • DRUG Chloroquine Phosphate

Study Locations (1)

Arizona

  • Clinical Trials Nurse Navigator - Scottsdale

Trial Details

FieldValue
Enrollment Target 6 participants
Start Date 2025-01-09
Est. Completion 2026-12
Phase Phase 1

Sponsor

HonorHealth Research Institute

20 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06076837

The ClinicalTrials.gov registry entry for NCT06076837 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 131-participant average among 9 other Pancreatic Cancer Metastatic trials with a reported enrollment target (95% lower). The listed sponsor is HonorHealth Research Institute, which has 20 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Pancreatic Cancer Metastatic appearing as the primary indexed condition, and to 5 interventions - of which Celecoxib is the first listed.

NCT06076837 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.

Frequently Asked Questions

What is clinical trial NCT06076837 about?

NCT06076837 is a clinical study titled "The Seven Trial: Exploiting the Unfolded Protein Response". The goal of this investigator initiated interventional study is to improve the response to the anticancer treatments (chemotherapy) in people who have previously untreated metastatic pancreas cancer. The main question it aims to answer is: • Do new types of immune-based therapies, called botensilim...

What is the current status of trial NCT06076837?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2025-01-09. Estimated completion is 2026-12.

What conditions does trial NCT06076837 study?

This clinical trial studies the following conditions: Pancreatic Cancer Metastatic, Pancreatic Adenocarcinoma Metastatic.

What interventions are being tested in trial NCT06076837?

The interventions under investigation include: Celecoxib (DRUG), Balstilimab (DRUG), Nab paclitaxel (DRUG), Botensilimab (DRUG), Chloroquine Phosphate (DRUG).

Who is sponsoring clinical trial NCT06076837?

This trial is sponsored by HonorHealth Research Institute, which has 20 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06076837 being conducted?

This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pancreatic Cancer Metastatic

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Pancreatic Cancer Metastatic

All registered trials for this condition

Pancreatic Adenocarcinoma Metastatic

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.